TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01974570

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Marealis refined peptide concentrate
Description: 2 tablets, once per day before noon

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 tablets, once per day before noon
Study: NCT00717873

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airway clearance Device
Description: Provided by the Vest Airway clearance system
Study: NCT02024698

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: omafilcon A
Description: contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A
Description: contact lens
Study: NCT02896855

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel (75-mg/m\^2) was administered by IV infusion every 3 weeks until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel (75-mg/m\^2) was administered by IV infusion every 3 weeks until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab (840-mg loading dose for Cycle 1, followed by 420 mg for subsequent cycles) was administered by IV infusion every 3 weeks until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo matched to pertuzumab was administered by IV infusion every 3 weeks until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab (8-mg/kg loading dose for Cycle 1, followed by 6 mg/kg for subsequent cycles) was administered by IV infusion every 3 weeks until disease progression or unacceptable toxicity.
Study: NCT02001428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dihydroartemisinin-piperaquine
Description: Participating infants with uncomplicated malaria will be treated with a three day course (1 dose/day) of DHP (containing 40 mg dihydroartemisinin and 320 mg piperaquine) administered as a total dose over three days of 6mg/kg of dihydroartemisinin and 57 mg/kg of piperaquine.
Study: NCT03437460

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 600 mg
Description: The investigators administer one single 600 mg dose of ibuprofen immediately before lunch. Participants are then asked to complete the cold pressor task, flower stringing sessions, and cognitive tasks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Prenatal vitamins
Description: The investigators administer one single prenatal multivitamin immediately before lunch. Participants are then asked to complete the cold pressor task, flower stringing sessions, and cognitive tasks.
Study: NCT00370396

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Synflorix
Description: 1 dose injected IM in the right thigh or deltoid.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Synflorix
Description: 1 dose injected IM in the right thigh or deltoid.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar
Description: 1 dose injected IM in the right thigh or deltoid.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix hexa
Description: 1 dose injected IM in the right thigh or deltoid.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix hexa
Description: 1 dose injected IM in the right thigh or deltoid.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix hexa
Description: 1 dose injected IM in the right thigh or deltoid.
Study: NCT00895583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: During the screening phase, tacrolimus is provided by the investigator (not the Sponsor) and is dosed to achieve a target trough level determined by the investigator. Therefore, the dosage form, dosage, and frequency are determined by the investigator. Duration of treatment is from transplantation until randomization (from 90 to 150 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Following randomization, sirolimus is provided by the Sponsor in 1 and 2 mg oral tablets. Sirolimus is dosed once daily to achieve a target trough level of 7 to 15 ng/mL in the 1st year post-transplant and 5 - 15 ng/mL in the 2nd year post-transplant. Duration of treatment is from randomization through 2 years post-transplant (19 to 21 months).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: During the study, tacrolimus is provided by the investigator (not the Sponsor) and is dosed to achieve a target trough level determined by the investigator. Therefore, the dosage form, dosage, and frequency are determined by the investigator. Duration of treatment is 2 years post-transplant.
Study: NCT06521034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FHND-9041
Description: In Phase I, using a 3+3 design, dose escalation and expansion studies were conducted at doses of 40, 80, 120 and 180 mg/day. At least 3 patients were enrolled in each dose arm, and no dose-limiting toxicities were observed. With a plateau observed at 120 mg/day, the 80 mg/d and 120mg/d groups were selected for dose expansion. The 80mg/d queue has expanded by 36 patients, and the 120mg/d queue has expanded by 39 patients. In Phase Ⅱ, after comprehensive analysis and consultation, at least 30 patients were enrolled according to the inclusion and exclusion criteria. 37 patients with locally advanced or metastatic EGFR-mutated NSCLC receiving first-line treatment were enrolled.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FHND-9041
Description: In Phase I, using a 3+3 design, dose escalation and expansion studies were conducted at doses of 40, 80, 120 and 180 mg/day. At least 3 patients were enrolled in each dose arm, and no dose-limiting toxicities were observed. With a plateau observed at 120 mg/day, the 80 mg/d and 120mg/d groups were selected for dose expansion. The 80mg/d queue has expanded by 36 patients, and the 120mg/d queue has expanded by 39 patients. In Phase Ⅱ, after comprehensive analysis and consultation, at least 30 patients were enrolled according to the inclusion and exclusion criteria. 37 patients with locally advanced or metastatic EGFR-mutated NSCLC receiving first-line treatment were enrolled.
Study: NCT00947518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: Baby wipes containing 0.25% free chlorhexidine (equivalent to 0.44% chlorhexidine digluconate)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Cleansing the skin (except the face)with baby wipes containing normal saline
Study: NCT02662608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brontictuzumab
Description: 1.5 mg/Kg intravenously every three weeks.
Study: NCT01584726

Intervention type: DRUG
Group type: OTHER
Intervention: Magnesium Sulfate
Description: single dose of magnesium sulfate nebulization
Study: NCT02481479

Intervention type: DRUG
Group type: OTHER
Intervention: Saxagliptin
Description: Eligible patients will undergo baseline CMR, commence treatment and then after 6 months undergo repeat CMR

Intervention type: DRUG
Group type: OTHER
Intervention: Saxagliptin
Description: Eligible patients will undergo baseline echocardiogram, commence treatment and then after 6 months undergo repeat echocardiogram

Intervention type: DRUG
Group type: OTHER
Intervention: saxagliptin
Description: Eligible patients will undergo baseline venipuncture, commence treatment and then after 6 months undergo repeat venipuncture
Study: NCT02545010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: All patients will receive weekly paclitaxel at a pre specified dose of 80 mg/m2, 70 mg/m2, 60mg/m2 or 50 mg/m2 via intravenous infusion according to institution specific standard practices.~Cycles of chemotherapy will be administered weekly without interruption on Days 1,8,15,22,29,36 for a total of 6 weekly cycles in combination with LDWART. Post treatment assessments will be conducted starting Day 43.~Patients will then continue chemotherapy off trial protocol with weekly paclitaxel without concurrent LDWART starting Day 50 till disease progression, intolerable toxicity, patient refusal or deemed inappropriate to continue treatment by treating physician.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: LDWART (Low Dose Whole Abdominal Radiation Therapy)
Description: LDWART will be given at 60 cGy fractions, twice daily for two days, with a minimum of 4 hours inter fraction interval, starting on day 1 of each cycle of weekly paclitaxel for 6 weeks.~LDWART will not be administered if doses of weekly paclitaxel are withheld for any reason since it functions as a chemosensitizer. LDWART will be administered together weekly paclitaxel immediately at point of recovery from toxicity and patient is deemed to be able to continue with treatment by investigator.
Study: NCT00216944

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tracheal intubation for respiratory care in preterm infants
Description: Premedication with atropine 0.02 mg/kg and morphine 0.03 mg/kg

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tracheal intubation for respiratory care in preterm infants
Description: Premedication with glycopyrronium 0.005 mg/kg, thiopental 2-3 mg/kg (\< 2 kg 2 mg/kg), suxamethonium 2 mg/kg and remifentanil 0.001 mg/kg
Study: NCT05102045

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: TMS is a non-invasive application that induces changes in neuronal polarization and activity by causing the induction of weak electric currents in a rapidly changing magnetic field. Repetitive TMS (rTMS) refers to the application of regular TMS pulses at fixed intervals.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Brisk exercise that promotes the circulation of oxygen through the blood and is associated with an increased rate of breathing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcholinesterase Inhibitors
Description: Donepezil, Rivastigmine, Galantamine were given in combination for Alzheimer's disease.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylcholinesterase Inhibitors
Description: Donepezil, Rivastigmine, Galantamine were given in combination for Alzheimer's disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcholinesterase Inhibitors
Description: Donepezil, Rivastigmine, Galantamine were given in combination for Alzheimer's disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Memantine were given for Alzheimer's disease. .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: Memantine were given for Alzheimer's disease. .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Memantine were given for Alzheimer's disease. .
Study: NCT03000868

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cold endoscopic mucosal resection
Description: Cold endoscopic mucosal resection (EMR) means removing small colorectal polyps (\<1cm) with snare without the use of electocautery after injection of normal saline into the submucosa.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hot endoscopic mucosal resection
Description: Hot endoscopic mucosal resection (EMR) means removing small colorectalpolyps (\<1cm) with snare without the use of electocautery after injection of normal saline into the submucosa.
Study: NCT01289431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mapracorat
Description: administered daily to each eye for 2 weeks following allergen challenge using a CAC model

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: administered daily to each eye for 2 weeks following allergen challenge using a CAC model
Study: NCT01906099

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nutritional intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: life style modification
Study: NCT03167814

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Diet group
Description: In the diet, there is no long-chain triglycerides. Fat and protein needs are met with adding medium-chain-fat acid as oil and protein supplements to the diet. Diet has been constructed together with clinical nutrition specialist.
Study: NCT05842577

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VRRS Tablet (Khymeia s.r.l., Noventa Padovana, Italy)
Description: The motor exercises were performed using inertial sensors for the acquisition and processing of the movement performed by the patient. The patient was trained to perform these exercises using visual and auditory feedback in a serious game environment. The exercises were aimed at the rehabilitation of balance and at the improvement of motor performance in lower limbs (e.g., maintaining balance on one leg, marching in place, standing on tiptoe, squatting, etc.). The therapists involved in the study customized the protocol of exercises in TR mode according to the characteristics and needs of the subject.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: At-home conventional rehabilitation
Description: The CG rehabilitation was an active comparator treatment and consisted of a written home-based self-administered booklet with conventional motor activities tailored for each subject. The motor activities were chosen and adapted from a specialized manual. The motor exercises were aimed at the rehabilitation of balance and at the improvement of motor performance in lower limbs (e.g., maintaining balance on one leg, marching in place, standing on tiptoe, squatting, etc).
Study: NCT03827499

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multicomponent physical exercise program
Description: Intervention groups including exercise (Ex-HMB and Ex-Plac) will complete an individualized multicomponent training program, five days a week during 24 weeks.
Study: NCT02393534

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone Visit
Description: Eligible patients that are randomized to the telephone follow-up arm will have their next medical visit with their primary care provider via a telephone call.
Study: NCT04364724

Intervention type: OTHER
Intervention: CT-based finite element analysis
Description: CTFEA is a computerized analysis of CT-scans which simulates stress testing of finite element models of various bones (in this study - femurs and vertebrae).~No intervention is planned - the study is observational. CT scans are performed for follow-up as an accepted standard of care. Secondary use of CT scans for CTFEA is in addition to the standard of care.~In a case when CTFEA analysis detects a high risk of pathologic fracture, the treating hematologist will be informed and will refer the patient for evaluation at the National Unit of Orthopedic Oncology.
Study: NCT02693678

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DIathermy

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham diathermy
Study: NCT03700528

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Description: The process will involve, two, brief, one-to-one contact sessions, one at the beginning and one at the end of the intervention, in a way that is convenient for participants, including Skype, phone, or face to face in person. Following the first one-to-one session there will be eight short online sessions, about 20-30 minutes each. Participants will also be asked to complete some tasks between the sessions, in particular to record their progress briefly and any changes at their medication (i.e. type of drug, dose) in a diary weekly so that they can keep track of your developing skills.
Study: NCT03806322

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent Pneumatic Compression
Description: The group received ultrasound, transcutaneous electrical nerve stimulation, electrical stimulation, exercise, and intermittent pneumatic compression.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold-pack
Description: The group received ultrasound, transcutaneous electrical nerve stimulation, electrical stimulation, exercise, and cold packs.
Study: NCT01331083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PX-866
Description: PX-866: 8mg orally taken daily
Study: NCT00630682

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextroamphetamine
Description: 1 week placebo and 8 weeks 60mg d-AMP QD.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 9 weeks of placebo 60mg capsules QD.
Study: NCT02557594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Viread 300mg
Description: single dose administration after 10hr fasting

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Viread 300mg
Description: single dose administration after 10hr fasting

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-2802 319mg
Description: single dose administration after 10hr fasting

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-2802 319mg
Description: single dose administration after 10hr fasting
Study: NCT02609282

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hourly prompts to stand delivered by Microsoft Outlook
Study: NCT01987700

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FLEX-HD

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FLEX-HD

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Strattice

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Strattice
Study: NCT04528628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRIs/SNRIs (Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors)
Description: Patients will be treated with one kind of selective serotonin reuptake inhibitors/ serotonin and norepinephrine reuptake inhibitors. Dose is titrated to the minimum effective dose within 2 weeks. Benzodiazepines can be used for a short period lasting no more than 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRIs/SNRIs (Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors)
Description: Patients will be treated with one kind of selective serotonin reuptake inhibitors/ serotonin and norepinephrine reuptake inhibitors. Dose is titrated to the minimum effective dose within 2 weeks. Benzodiazepines can be used for a short period lasting no more than 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRIs/SNRIs (Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors)
Description: Patients will be treated with one kind of selective serotonin reuptake inhibitors/ serotonin and norepinephrine reuptake inhibitors. Dose is titrated to the minimum effective dose within 2 weeks. Benzodiazepines can be used for a short period lasting no more than 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRIs/SNRIs (Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors)
Description: Patients will be treated with one kind of selective serotonin reuptake inhibitors/ serotonin and norepinephrine reuptake inhibitors. Dose is titrated to the minimum effective dose within 2 weeks. Benzodiazepines can be used for a short period lasting no more than 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: The research doctor discusses the treatment plan with the patient, and therapies and drugs are not limited.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: The research doctor discusses the treatment plan with the patient, and therapies and drugs are not limited.
Study: NCT03827499

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Multicomponent physical exercise program
Description: Intervention groups including exercise (Ex-HMB and Ex-Plac) will complete an individualized multicomponent training program, five days a week during 24 weeks.
Study: NCT04528628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: The research doctor discusses the treatment plan with the patient, and therapies and drugs are not limited.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: The research doctor discusses the treatment plan with the patient, and therapies and drugs are not limited.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SSRIs/SNRIs (Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors) Combined with Magnetic Stimulations
Description: Drug therapies are the same as the SSRIs/SNRIs monotherapy group. Patients will randomly receive one kind of magnetic stimulations including repetitive transcranial magnetic stimulation (rTMS), continuous theta burst stimulation(cTBS) and intermittent theta burst stimulation (iTBS) at a ratio of 1:1:1.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SSRIs/SNRIs (Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors) Combined with Magnetic Stimulations
Description: Drug therapies are the same as the SSRIs/SNRIs monotherapy group. Patients will randomly receive one kind of magnetic stimulations including repetitive transcranial magnetic stimulation (rTMS), continuous theta burst stimulation(cTBS) and intermittent theta burst stimulation (iTBS) at a ratio of 1:1:1.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SSRIs/SNRIs (Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors) Combined with Magnetic Stimulations
Description: Drug therapies are the same as the SSRIs/SNRIs monotherapy group. Patients will randomly receive one kind of magnetic stimulations including repetitive transcranial magnetic stimulation (rTMS), continuous theta burst stimulation(cTBS) and intermittent theta burst stimulation (iTBS) at a ratio of 1:1:1.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SSRIs/SNRIs (Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors) Combined with Magnetic Stimulations
Description: Drug therapies are the same as the SSRIs/SNRIs monotherapy group. Patients will randomly receive one kind of magnetic stimulations including repetitive transcranial magnetic stimulation (rTMS), continuous theta burst stimulation(cTBS) and intermittent theta burst stimulation (iTBS) at a ratio of 1:1:1.
Study: NCT02767622

Intervention type: PROCEDURE
Intervention: Liver transplantation